Avanos Medical, Inc. - Understand $avns stock

$AVNS Market Cap: $877.8 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$681.5M

TTM

Gross Margin

55.52%

TTM

Net Earnings

$15.70M

TTM

Current Assets

$472.6M

Q3 2024

Current Liabilities

$212.9M

Q3 2024

Current Ratio

221.98%

Q3 2024

Total Assets

$1.656B

Q3 2024

Total Liabilities

$426.5M

Q3 2024

Book Value

$1.230B

Q3 2024

Cash

$89.00M

Q3 2024

P/E

55.91

Nov 29, 2024 EST

Free Cash Flow

$36.60M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$673.3M	$820.0M	$744.6M	$714.8M	$697.6M	$652.3M	$611.6M	$566.2M	$509.0M	$1.672B	$1.678B	$1.684B	$1.660B
YoY Change	-17.89%	10.13%	4.17%	2.47%	6.94%	6.65%	8.02%	11.24%	-69.56%	-0.32%	-0.39%	1.45%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$673.3M	$820.0M	$744.6M	$714.8M	$697.6M	$652.3M	$611.6M	$566.2M	$509.0M	$1.672B	$1.678B	$1.684B	$1.660B
Cost Of Revenue	$293.6M	$370.0M	$380.3M	$341.5M	$295.4M	$261.4M	$274.7M	$269.0M	$251.2M	$1.124B	$1.065B	$1.082B	$1.069B
Gross Profit	$379.7M	$450.0M	$364.3M	$373.3M	$402.2M	$390.9M	$336.9M	$297.2M	$257.8M	$548.6M	$612.2M	$602.5M	$590.8M
Gross Profit Margin	56.39%	54.88%	48.93%	52.22%	57.65%	59.93%	55.09%	52.49%	50.65%	32.81%	36.49%	35.78%	35.59%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$335.0M	$341.9M	$300.3M	$332.6M	$399.1M	$340.4M	$321.7M	$346.2M	$349.7M	$424.5M	$351.4M	$343.0M	$351.7M
YoY Change	-2.02%	13.85%	-9.71%	-16.66%	17.24%	5.81%	-7.08%	-1.0%	-17.62%	20.8%	2.45%	-2.47%
% of Gross Profit	88.23%	75.98%	82.43%	89.1%	99.23%	87.08%	95.49%	116.49%	135.65%	77.38%	57.4%	56.93%	59.53%
Research & Development	$27.20M	$30.60M	$32.30M	$34.90M	$37.70M	$41.80M	$38.20M	$38.40M	$27.60M	$33.60M	$37.90M	$33.00M	$31.20M
YoY Change	-11.11%	-5.26%	-7.45%	-7.43%	-9.81%	9.42%	-0.52%	39.13%	-17.86%	-11.35%	14.85%	5.77%
% of Gross Profit	7.16%	6.8%	8.87%	9.35%	9.37%	10.69%	11.34%	12.92%	10.71%	6.12%	6.19%	5.48%	5.28%
Depreciation & Amortization	$46.10M	$47.70M	$38.30M	$42.90M	$36.90M	$33.50M	$59.50M	$65.20M	$65.40M	$85.40M	$69.20M	$57.60M	$51.10M
YoY Change	-3.35%	24.54%	-10.72%	16.26%	10.15%	-43.7%	-8.74%	-0.31%	-23.42%	23.41%	20.14%	12.72%
% of Gross Profit	12.14%	10.6%	10.51%	11.49%	9.17%	8.57%	17.66%	21.94%	25.37%	15.57%	11.3%	9.56%	8.65%
Operating Expenses	$362.2M	$372.5M	$332.6M	$367.5M	$436.8M	$382.2M	$359.9M	$384.6M	$377.3M	$458.1M	$389.3M	$376.0M	$380.1M
YoY Change	-2.77%	12.0%	-9.5%	-15.87%	14.29%	6.2%	-6.42%	1.93%	-17.64%	17.67%	3.54%	-1.08%
Operating Profit	$4.200M	$74.00M	$8.900M	-$46.10M	-$55.70M	$500.0K	-$43.10M	-$107.1M	-$135.7M	$94.30M	$225.3M	$228.0M	$210.7M
YoY Change	-94.32%	731.46%	-119.31%	-17.24%	-11240.0%	-101.16%	-59.76%	-21.08%	-243.9%	-58.14%	-1.18%	8.21%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$15.00M	$10.00M	$3.300M	$15.60M	$15.00M	$26.40M	$31.60M	$32.70M	$33.10M	$6.000M	$100.0K	$800.0K	$3.900M
YoY Change	50.0%	203.03%	-78.85%	4.0%	-43.18%	-16.46%	-3.36%	-1.21%	451.67%	5900.0%	-87.5%	-79.49%
% of Operating Profit	357.14%	13.51%	37.08%			5280.0%				6.36%	0.04%	0.35%	1.85%
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$7.900M	$65.20M	$5.800M	-$60.50M	-$64.00M	-$18.10M	-$72.20M	-$139.2M	-$168.5M	$91.20M	$227.8M	$229.8M	$214.6M
YoY Change	-112.12%	1024.14%	-109.59%	-5.47%	253.59%	-74.93%	-48.13%	-17.39%	-284.76%	-59.96%	-0.87%	7.08%
Income Tax	$2.000M	$14.70M	$600.0K	-$33.30M	-$18.10M	-$9.600M	-$40.10M	-$55.90M	-$67.30M	$64.10M	$73.20M	$77.20M	$72.20M
% Of Pretax Income		22.55%	10.34%							70.29%	32.13%	33.59%	33.64%
Net Earnings	-$61.80M	$50.50M	$5.200M	-$27.20M	-$45.90M	$57.50M	$79.30M	$39.80M	-$426.3M	$27.10M	$154.6M	$152.6M	$142.4M
YoY Change	-222.38%	871.15%	-119.12%	-40.74%	-179.83%	-27.49%	99.25%	-109.34%	-1673.06%	-82.47%	1.31%	7.16%
Net Earnings / Revenue	-9.18%	6.16%	0.7%	-3.81%	-6.58%	8.81%	12.97%	7.03%	-83.75%	1.62%	9.22%	9.06%	8.58%
Basic Earnings Per Share	-$1.32	$1.08	$0.11	-$0.57	-$0.96	$1.22	$1.69	$0.85	-$9.15	$0.58	$3.32	$3.28
Diluted Earnings Per Share	-$1.32	$1.07	$0.11	-$0.57	-$0.96	$1.22	$1.69	$0.85	-$9.15	$0.58	$3.32	$3.28	$3.062M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$87.70M	$127.7M	$118.5M	$111.5M	$205.3M	$384.5M	$219.7M	$113.7M	$129.5M	$149.0M	$44.10M	$47.90M
YoY Change	-31.32%	7.76%	6.28%	-45.69%	-46.61%	75.01%	93.23%	-12.2%	-13.09%	237.87%	-7.93%
Cash & Equivalents	$87.70M	$127.7M	$118.5M	$111.5M	$205.3M	$384.5M	$219.7M	$113.7M	$129.5M	$149.0M	$44.10M	$47.90M
Short-Term Investments
Other Short-Term Assets	$93.30M	$13.90M	$18.60M	$18.90M	$23.50M	$57.20M	$646.9M	$17.20M	$18.60M	$18.90M	$52.10M	$60.40M
YoY Change	571.22%	-25.27%	-1.59%	-19.57%	-58.92%	-91.16%	3661.05%	-7.53%	-1.59%	-63.72%	-13.74%
Inventory	$163.2M	$190.3M	$150.3M	$168.9M	$145.9M	$121.4M	$91.10M	$272.5M	$303.2M	$283.1M	$285.6M	$301.7M
Prepaid Expenses
Receivables	$142.8M	$155.7M	$118.2M	$108.6M	$163.8M	$150.5M	$203.0M	$190.1M	$224.7M	$233.9M	$203.3M	$183.7M
Other Receivables	$0.00	$12.20M	$13.00M	$59.30M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$487.0M	$499.8M	$418.6M	$467.2M	$538.5M	$713.6M	$1.161B	$593.5M	$676.0M	$684.9M	$585.1M	$593.7M
YoY Change	-2.56%	19.4%	-10.4%	-13.24%	-24.54%	-38.52%	95.57%	-12.2%	-1.3%	17.06%	-1.45%
Property, Plant & Equipment	$144.0M	$194.5M	$206.7M	$223.6M	$248.5M	$154.1M	$109.9M	$260.8M	$279.5M	$277.8M	$324.9M	$325.7M
YoY Change	-25.96%	-5.9%	-7.56%	-10.02%	61.26%	40.22%	-57.86%	-6.69%	0.61%	-14.5%	-0.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$25.80M	$22.20M	$26.50M	$21.80M	$27.40M	$13.90M	$11.70M	$18.70M	$16.90M	$30.50M	$2.700M	$3.900M
YoY Change	16.22%	-16.23%	21.56%	-20.44%	97.12%	18.8%	-37.43%	10.65%	-44.59%	1029.63%	-30.77%
Total Long-Term Assets	$1.205B	$1.287B	$1.176B	$1.206B	$1.261B	$1.120B	$1.035B	$1.478B	$1.324B	$1.843B	$1.899B	$1.941B
YoY Change	-6.35%	9.45%	-2.46%	-4.4%	12.62%	8.17%	-29.97%	11.64%	-28.14%	-2.96%	-2.14%
Total Assets	$1.692B	$1.787B	$1.595B	$1.673B	$1.800B	$1.833B	$2.196B	$2.072B	$2.000B	$2.528B	$2.484B	$2.534B
YoY Change
Accounts Payable	$56.30M	$67.90M	$56.40M	$67.60M	$83.00M	$169.9M	$171.2M	$173.1M	$163.2M	$168.7M	$118.5M	$102.2M
YoY Change	-17.08%	20.39%	-16.57%	-18.55%	-51.15%	-0.76%	-1.1%	6.07%	-3.26%	42.36%	15.95%
Accrued Expenses	$106.0M	$111.7M	$82.80M	$98.70M	$129.5M	$94.40M	$144.9M	$151.3M	$152.0M	$175.6M	$180.0M	$181.0M
YoY Change	-5.1%	34.9%	-16.11%	-23.78%	37.18%	-34.85%	-4.23%	-0.46%	-13.44%	-2.44%	-0.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$3.900M	$11.90M	$75.90M
YoY Change									-100.0%	-67.23%	-84.32%
Long-Term Debt Due	$8.600M	$6.200M	$0.00			$0.00	$39.80M
YoY Change	38.71%					-100.0%
Total Short-Term Liabilities	$234.6M	$185.8M	$139.2M	$166.3M	$212.5M	$264.3M	$389.8M	$324.4M	$315.2M	$356.0M	$310.4M	$359.1M
YoY Change	26.26%	33.48%	-16.3%	-21.74%	-19.6%	-32.2%	20.16%	2.92%	-11.46%	14.69%	-13.56%
Long-Term Debt	$159.4M	$226.3M	$130.0M	$180.0M	$248.1M	$247.7M	$541.1M	$579.0M	$578.1M	$632.3M	$0.00	$0.00
YoY Change	-29.56%	74.08%	-27.78%	-27.45%	0.16%	-54.22%	-6.55%	0.16%	-8.57%
Other Long-Term Liabilities	$38.30M	$58.20M	$51.90M	$64.30M	$73.80M	$19.80M	$31.80M	$30.10M	$27.80M	$20.20M	$4.000M	$23.00M
YoY Change	-34.19%	12.14%	-19.28%	-12.87%	272.73%	-37.74%	5.65%	8.27%	37.62%	405.0%	-82.61%
Total Long-Term Liabilities	$197.7M	$284.5M	$181.9M	$244.3M	$321.9M	$267.5M	$572.9M	$609.1M	$605.9M	$652.5M	$4.000M	$23.00M
YoY Change	-30.51%	56.4%	-25.54%	-24.11%	20.34%	-53.31%	-5.94%	0.53%	-7.14%	16212.5%	-82.61%
Total Liabilities	$456.1M	$495.7M	$330.7M	$416.3M	$534.4M	$536.2M	$980.5M	$969.3M	$944.9M	$1.036B	$404.9M	$478.5M
YoY Change	-7.99%	49.89%	-20.56%	-22.1%	-0.34%	-45.31%	1.16%	2.58%	-8.83%	155.96%	-15.38%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Basic Shares Outstanding	46.60M shares	46.90M shares	48.10M shares	47.80M shares	47.60M shares	47.20M shares	46.80M shares	46.60M shares	46.60M shares	46.50M shares	46.50M shares
Diluted Shares Outstanding	46.60M shares	47.30M shares	48.60M shares	47.80M shares	47.60M shares	47.20M shares	46.80M shares	46.60M shares	46.60M shares	46.50M shares	46.50M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $877.78 Million

About AVANOS MEDICAL, INC.

Avanos Medical, Inc. is a medical technology company, which engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company is headquartered in Alpharetta, Georgia and currently employs 3,771 full-time employees. The company went IPO on 2014-10-21. The firm offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The firm conducts its business in one segment that provides its medical device products to healthcare providers and patients globally with manufacturing facilities in the United States and Mexico. Its digestive health products include MIC-KEY enteral feeding tubes, Corpak patient feeding solutions and NeoMed neonatal and pediatric feeding solutions. The Company’s acute pain products include ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems. The firm's interventional pain solutions include COOLIEF pain therapy and OrthogenRxs knee osteoarthritis pain relief injection products.

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: ATRION CORP Embecta Corp. BIOLIFE SOLUTIONS INC FIGS, Inc. MERIDIAN BIOSCIENCE INC MERIT MEDICAL SYSTEMS INC ORTHOPEDIATRICS CORP Silk Road Medical Inc UFP TECHNOLOGIES INC